Best Value Stocks to Buy for September 22nd

Zacks named Bausch Health, OptimumBank Holdings and Trivago as #1 Rank value stocks on September 22 following upward current-year earnings-estimate revisions of 7.4%, 16.5% and 8.7%, respectively, over the past 60 days. The article is a stock-selection screen rather than a material company update, implying limited broad market impact.

Analysis

The estimate revisions are too narrow and promotional in origin to justify a broad factor signal. BHC is the only name with institutional liquidity sufficient for a tactical reaction, but its equity remains governed by leverage, litigation/regulatory exposure and the timing/value realization of its Bausch + Lomb stake; a modest earnings revision does not resolve those balance-sheet variables. For OPHC, the apparent revision has little portfolio relevance absent confirmation of deposit growth, uninsured-deposit concentration, CRE losses and tangible-common-equity accretion; micro-cap bank liquidity can turn a positive screen into an untradeable gap risk.

TRVG's incremental estimate momentum is more interesting as a read-through on hotel metasearch marketing efficiency than on travel demand. A sustained recovery would pressure customer-acquisition economics at online travel agencies, but only if Trivago demonstrates revenue growth without materially increasing performance-marketing spend; Google search-product changes and AI-generated travel discovery remain the larger 6-18 month structural threat. The market should not extrapolate a screen-based revision into a durable competitive turnaround.

The attached quantum-computing promotion is not investable evidence of near-term hyperscaler capex or revenue. MSFT, GOOG, AMZN and ORCL can fund quantum R&D without a measurable earnings impact for years, while QUBT remains a sentiment/liquidity vehicle rather than a clean proxy for commercial adoption. Consensus may overreact to any retail-driven quantum basket move; the better signal would be disclosed paid cloud usage, bookings, or procurement commitments rather than partnership language.

Key Decisions for Investors

• No new position in OPHC or QUBT: require average daily dollar volume, updated call-report deposit/CRE data for OPHC, and independently disclosed recurring revenue/backlog for QUBT before considering exposure.
• Place BHC on a 1-3 month event watchlist rather than chase estimate momentum; consider a tactical long only if next results show FCF sufficient to reduce leverage and management advances a credible Bausch + Lomb monetization path. Exit on weaker FCF guidance or any leverage increase.
• Monitor TRVG next-quarter revenue growth against sales-and-marketing growth. If revenue accelerates while marketing intensity declines, initiate a small 3-6 month long TRVG versus short EXPE as a metasearch-efficiency pair; invalidate if traffic gains require higher paid-search spend or Google referral trends deteriorate.
• Fade quantum-themed retail spikes through a small QUBT short only after a >25% news-driven move with no new contracted-revenue disclosure; use a hard stop on verified customer/bookings announcements, given borrow and squeeze risk.